Among patients with ulcerative colitis only those with severe cases S3 received biological therapy p <0.001, and there was no significant difference related to the extension of the disease.
En colitis ulcerativa solo los pacientes con enfermedad severa S3 recibieron terapia biológica p < 0,001 y no hubo diferencia significativa con la extensión de la enfermedad.